Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

MDGN-002 · AVTX-002, AEVI-002

Monoclonal antibody · Antagonist of LIGHT (TNFSF14) (TNFSF14) · developed by Avalo Therapeutics

Phase 1 Most advanced trial (none active)
AVTX Developer
1 Registered trials

What is MDGN-002?

MDGN-002 is a fully human IgG4 monoclonal antibody that binds human LIGHT. It is being studied in Crohn disease and ulcerative colitis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
AVTX-002, AEVI-002
Drug type
Monoclonal antibody
Targets
LIGHT (TNFSF14) (TNFSF14)
Mechanism
Antagonist of LIGHT (TNFSF14) (TNFSF14)
Therapy area
Gastroenterology
Developer
Avalo Therapeutics, Inc. (AVTX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
M46KZB8QXL

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03169894 Phase 1 Crohn Disease Terminated AVTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Crohn DiseaseUlcerative Colitis

More from Avalo Therapeutics

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the AVTX page.

Follow AVTX, the company behind MDGN-002

See AVTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AVTX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.